Sandbox Reserved 598: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 40: | Line 40: | ||
There are currently many therapies for differing forms of leukemia, some of which include cytoreductive medications such as hydroxyurea or agrylin, to suppress the bone marrow’s ability to make blood cells, cell destructive medications like cytoxin which act as oral chemotheraputic agents, interferon treatments to stimulate the patient's immune response to fight and kill overproduction or white and red blood cells. Finally traditional chemotherapy is commonly used, as well, for both leukemias as well as progressive polycythemia vera. <ref> http://m.cancer.gov/topics/treatment/bycancer/adultAML/Patient </ref> <ref> http://www.mayoclinic.com/health/chronic-lymphocytic-leukemia/DS00565 </ref> <ref> http://www.mayoclinic.com/health/polycythemia-vera/DS00919 </ref> <ref> Medscape Reference (01, 2012, 10) Polycythemia Treatment and Management. Retrieved from: http://emedicine.medscape.com/article/205114-treatment </ref> While there are a few Jak2 inhibitors already in use which use competitive inhibition for ATP binding pockets, they are not extremely effective due to non-specificity. Due to this issue with specificity, the current therapies for Jak2 mutations are being more focused on allosteric inhibition designs. This research is believed to be hopeful due to the successes it has had with other, different, kinase inhibition. Possible sites which scientists are targeting for such inhibition include, the type II Inhibitor pocket, substrate binding sites, kinase pseudo kinase domain interface, SH2JK2 Linker Region, and the FERM Domain. Currently many of these are in both pre and post clinical trials. <ref> Gnanasambandan, K., & Sayeski, P. (2011). A structure-function perspective of jak2 mutations and implications for alternate drug design strategies: the road not taken. Department of Physiology and Functional Genomics, University of Florida College of Medicine, 18(30), 59-73. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21864276 http://www.ncbi.nlm.nih.gov/pubmed/21864276 </ref> | There are currently many therapies for differing forms of leukemia, some of which include cytoreductive medications such as hydroxyurea or agrylin, to suppress the bone marrow’s ability to make blood cells, cell destructive medications like cytoxin which act as oral chemotheraputic agents, interferon treatments to stimulate the patient's immune response to fight and kill overproduction or white and red blood cells. Finally traditional chemotherapy is commonly used, as well, for both leukemias as well as progressive polycythemia vera. <ref> http://m.cancer.gov/topics/treatment/bycancer/adultAML/Patient </ref> <ref> http://www.mayoclinic.com/health/chronic-lymphocytic-leukemia/DS00565 </ref> <ref> http://www.mayoclinic.com/health/polycythemia-vera/DS00919 </ref> <ref> Medscape Reference (01, 2012, 10) Polycythemia Treatment and Management. Retrieved from: http://emedicine.medscape.com/article/205114-treatment </ref> While there are a few Jak2 inhibitors already in use which use competitive inhibition for ATP binding pockets, they are not extremely effective due to non-specificity. Due to this issue with specificity, the current therapies for Jak2 mutations are being more focused on allosteric inhibition designs. This research is believed to be hopeful due to the successes it has had with other, different, kinase inhibition. Possible sites which scientists are targeting for such inhibition include, the type II Inhibitor pocket, substrate binding sites, kinase pseudo kinase domain interface, SH2JK2 Linker Region, and the FERM Domain. Currently many of these are in both pre and post clinical trials. <ref> Gnanasambandan, K., & Sayeski, P. (2011). A structure-function perspective of jak2 mutations and implications for alternate drug design strategies: the road not taken. Department of Physiology and Functional Genomics, University of Florida College of Medicine, 18(30), 59-73. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21864276 http://www.ncbi.nlm.nih.gov/pubmed/21864276 </ref> | ||
==References== | |||
<references /> | |||
